Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine

Virology

Volumn 468, Issue , 2014, Pages 283-292

  Diaz San Segundo, Fayna ^a   Dias, Camila C ^a,b   Moraes, Mauro P ^a,c,e   Weiss, Marcelo ^a,b   Perez Martin, Eva ^a,b   Salazar, Andres M ^d   Grubman, Marvin J ^a   de los Santos, Teresa ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d Washington   (United States)

^e Ceva Biomune   (United States)

Author keywords

Adjuvants; Cell mediated immunity; Foot and mouth disease; Foot and mouth disease virus; Neutralizing antibodies; Poly ICLC; Replication defective adenovirus; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; DOUBLE STRANDED RNA; FOOT AND MOUTH DISEASE VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS RNA; CARBOXYMETHYLCELLULOSE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYLYSINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CATTLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; FEMALE; FOOT AND MOUTH DISEASE; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNOGENICITY; INFECTION PREVENTION; LIVESTOCK; LOW DRUG DOSE; NONHUMAN; SEROTYPE; SWINE; VACCINATION; VIREMIA; VIRUS CAPSID; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CONTROLLED CLINICAL TRIAL; FOOT-AND-MOUTH DISEASE; GENE VECTOR; HEK293 CELL LINE; HUMAN ADENOVIRUS; IMMUNOLOGY; SWINE DISEASES;

ADENOVIRIDAE; FOOT-AND-MOUTH DISEASE VIRUS; HUMAN ADENOVIRUS;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CARBOXYMETHYLCELLULOSE SODIUM; FOOT-AND-MOUTH DISEASE; GENETIC VECTORS; HEK293 CELLS; HUMANS; POLY I-C; POLYLYSINE; SWINE; SWINE DISEASES; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84907455151     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.08.012     Document Type: Article

References (61)

1. Aldabe R., Carrasco L. Induction of membrane proliferation by poliovirus proteins 2C and 2BC. Biochem. Biophys. Res. Commun. 1995, 206:64-76.
2. Arzt J., Pacheco J.M., Rodriguez L.L. The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation. Identification of the nasopharynx as the primary site of infection. Vet. Pathol. 2010, 47:1048-1063.
3. Baer G.M., Moore S.A., Shaddock J.H., Levy H.B. An effective rabies treatment in exposed monkeys: a single dose of interferon inducer and vaccine. Bull. World Health Organ. 1979, 57:807-813.
4. Buenz E.J., Howe C.L. Picornaviruses and cell death. Trends Microbiol. 2006, 14:28-36.
5. Cao Y., Lu Z., Li D., Fan P., Sun P., Bao H., Fu Y., Li P., Bai X., Chen Y., Xie B., Liu Z. Evaluation of cross-protection against three topotypes of serotype O foot-and-mouth disease virus in pigs vaccinated with multi-epitope protein vaccine incorporated with poly(I:C). Vet. Microbiol. 2014, 168:294-301.
6. Cao Y., Lu Z., Li P., Sun P., Fu Y., Bai X., Bao H., Chen Y., Li D., Liu Z. Improved neutralising antibody response against foot-and-mouth-disease virus in mice inoculated with a multi-epitope peptide vaccine using polyinosinic and polycytidylic acid as an adjuvant. J. Virol. Methods 2012, 185:124-128.
7. Cao Y., Lu Z., Li Y., Sun P., Li D., Li P., Bai X., Fu Y., Bao J., Zhou C., Xie B., Chen Y., Liu Z. Poly(I:C) combined with multi-epitope protein vaccine completely protects against virulent foot-and-mouth disease virus challenge in pigs. Antiviral Res. 2013, 97:145-153.
8. Caskey M., Lefebvre F., Filali-Mouhim A., Cameron M.J., Goulet J.P., Haddad E.K., Breton G., Trumpfheller C., Pollak S., Shimeliovich I., Duque-Alarcon A., Pan L., Nelkenbaum A., Salazar A.M., Schlesinger S.J., Steinman R.M., Se'kaly R.P. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011, 208:2357-2366.
9. Cho M.W., Teterina N., Egger D., Bienz K., Ehrenfeld E. Membrane rearrangement and vesicle induction by recombinant poliovirus 2C and 2BC in human cells. Virology 1994, 202:129-145.
10. de Avila Botton S., Brum M.C.S., Bautista E., Koster M., Weiblen R., Golde W.T., Grubman M.J. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006, 24:3446-3456.
11. de Jong A.S., Schrama I.W., Willems P.H., Galama J.M., Melchers W.J., van Kuppeveld F.J. Multimerization reactions of coxsackievirus proteins 2B, 2C and 2BC: a mammalian two-hybrid analysis. J. Gen. Virol. 2002, 83:783-793.
12. Dias C.C., Moraes M.P., Weiss M., Diaz-San Segundo F., Perez-Martin E., Salazar A.M., de los Santos T., Grubman M.J. Novel antiviral therapeutics to control foot-and-mouth disease. J. Int. Cyt. Res. 2012, 32:1-12.
13. Díaz-San Segundo F., Weiss M., Koster M.J., Dias C.C., Grubman M.J., de los Santos T. Inoculation of swine with foot-and-mouth disease SAP-mutant virus induces early protection against disease. J. Virol. 2012, 86:1316-1327.
14. Domingo E., Holland J.J. High error rates, population equilibrium and evolution of RNA replication systems. RNA Genetics, Vol. III. Variability of RNA Genomes 1988, 3-36. CRC Press, Boca Raton, Fl, USA. E. Domingo, J.J. Holland, P. Ahlquist (Eds.).
15. Du Y., Jiang P., Li Y., He H., Jiang W., Wang X., Hong W. Immune responses of two recombinant adenoviruses expressing VP1 antigens of FMDV fused with porcine granulocyte macrophage colony-stimulating factor. Vaccine 2007, 25:8209-8219.
16. Du Y., Li Y., He H., Qi J., Jiang W., Wang X., Tang B., Cao J., Wang X., Jiang P. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine. J. Virol. Methods 2008, 149:144-152.
17. Du Y., Dai J., Li Y., Li C., Qi J., Duan S., Jiang P. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs. Vet. Immunol. Immunopathol. 2008, 124:274-283.
18. Flynn B.J., Kastenmüller K., Wille-Reece U., Tomaras G.D., Alam M., Lindsay R.W., Salazar A.M., Perdiguero B., Gomez C.E., Wagner R., Esteban M., Park C.G., Trumpfheller C., Keler T., Pantaleo G., Steinman R.M., Seder R. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc. Natl. Acad. Sci. USA 2011, 26:7131-7136.
19. García-Briones M., Rosas M.F., González-Magaldi M., Martín-Acebes M.A., Sobrino F., Armas-Portela R. Differential distribution of non-structural proteins of foot-and-mouth disease virus in BHK-21 cells. Virology 2006, 349:409-421.
20. Graham F.L., Prevec L. Manipulation of adenovirus vectors. Methods In Molecular Biology 1991, 109-128. The Humana Press, Clinton, NJ. E.J. Murray (Ed.).
21. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 2004, 17:227-234.
22. Grubman M.J., Diaz-San Segundo F., Dias C.C.A., Moraes M.P., Perez-Martin E., de los Santos T. Use of replication-defective adenoviruses to develop vaccines and biotherapeutics against foot-and-mouth disease. Future Virol. 2012, 7(8):767-778.
23. Grubman M.J., Moraes M.P., Schutta C., Barrera J., Nielan J., Ettyreddy D., Butman B.T., Brough D.E., Brake D.A. Replication-defective human adenovirus serotype 5 vectored foot-and-mouth disease subunit vaccines: the first decade. Future Virol. 2010, 5:51-64.
24. Harrington D.G., Crabbs C.L., Hilmas D.E., Brown J.R., Higbee G.A., Cole F.E., Levy H.B. Adjuvant effects of low doses of nuclease-resistant derivative of polyinosinic acid polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine. Infect. Immun. 1979, 24:160-166.
25. Houston W.E., Crabbs C.L., Stephen E.L., Levy H.B. Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect. Immun. 1976, 14:318-319.
26. Kende M. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice. J. Biol. Response Modif. 1985, 4:503-511.
27. Kende M., Lupton H.W., Rill W.L., Levy H.B., Canonico P.G. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrob. Agents Chemother. 1987, 31:986-990.
28. Kool M., Soullie T., Van Nimwegen M., Willart M.A., Muskens F., Jung S., Hoogsteden H.C., Hammad H., Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 2008, 205:869-882.
29. Levy H.B., Baer G., Baron S., Buckler C.E., Gibbs C.J., Iadarola M.J., London W.T., Rice J.A. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 1975, 132:434-439.
30. Levy H.B., London W., Fuccillo D.A., Baron S., Rice J. Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer polyriboinosinic-polyribocytidylic acid-poly-l-lysine. J. Infect. Dis. 1976, (133 Suppl.):A256-A259.
31. Li Y., Hu Y., Jin Y., Zhang G., Wong J., Sun L.Q., Wang M. Prophylactic, therapeutic and immune enhanced effect of liposome-encapsulated poly ICLC on highly pathogenic H5N1 influenza infection. J. Gene Med. 2011, 13:60-72.
32. Martins K.A.O., Steffens J.T., van Tongeren S.A., Wells J.B., Bergeron A.A., Dickson S.P., Dye J.M., Salazar A.M., Bavari S. Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS One 2014, 9:e89735.
33. Mason P.W., Grubman M.J. Foot-and-mouth disease. Vaccines for Biodefense and Emerging and Neglected Diseases 2008, 359-376. (Chapter 22), Elsevier Press, London, U.K. A. Barrett, L. Stanberry (Eds.).
34. Mason P.W., Grubman M.J., Baxt B. Molecular basis of pathogenesis of FMDV. Foot-And-Mouth Disease 2003, (Virus Res. 91, 9-32). D. Rowlands (Ed.).
35. Mason P.W., Piccone M.E., McKenna TSt.-C., Chinsangaram J., Grubman M.J. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology 1997, 227:96-102.
36. Mayr G.A., Chinsangaram J., Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 1999, 263:496-506.
37. Mayr G.A., O'Donnell V., Chinsangaram J., Mason P.W., Grubman M.J. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 2001, 19:2152-2162.
38. Meylan E., Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell 2006, 22:561-569.
39. Moffat K., Howell G., Knox C., Belsham G.J., Monaghan P., Ryan M.D., Wileman T. Effects of foot-and-mouth disease virus nonstructural proteins on the structure and function of the early secretory pathway: 2BC but not 3 A blocks endoplasmic reticulum-to-golgi transport. J. Virol. 2005, 79:4382-4395.
40. Monaghan P., Cook H., Jackson T., Ryan M., Wileman T. The ultrastructure of the developing replication site in foot-and-mouth disease virus-infected BHK-38 cells. J. Gen. Virol. 2004, 85:933-946.
41. Moraes M.P., de los Santos T., Koster M., Turecek T., Wang H., Andreyev V.G., Grubman M.J. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J. Virol. 2007, 81:7124-7135.
42. Moraes M.P., Mayr G.A., Grubman M.J. pAd5-Blue: an easy to use, efficient, direct ligation system for engineering recombinant adenovirus constructs. BioTechniques 2001, 31:1050-1056.
43. Moraes M.P., Díaz-San Segundo F., Dias C.C.A., Pena L., Grubman M.J. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response. Vaccine 2011, 29:9431-9440.
44. Moraes M.P., Mayr G.A., Mason P.W., Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002, 20:1631-1639.
45. Ngoi S.M., Tovey M.G., Vella A.T. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. J. Immunol. 2008, 181(11):7670-7680.
46. Nordlund J.J., Wolff S.M., Levy H.B. Inhibition of biologic activity of poly I:poly C by human plasma. Proc. Soc. Exp. Biol. Med. 1970, 133:439-444.
47. OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2004, 111-128. (Modified May, 2006. Section 2.1 List A diseases. Chapter 2.1.1 Foot and mouth disease). Fifth edition.
48. Pacheco J.M., Brum M.C.S., Moraes M.P., Golde W.T., Grubman M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus vectored FMDV subunit vaccine. Virology 2005, 337:205-209.
49. Park H., Adamson L., Ha T., Mullen K., Hagen S.I., Nogueron A., Sylwester A.W., Axthelm M.K., Legasse A., Piatak M., Lifson J.D., McElrath J.M., Picker L.J., Seder R.A. Polyinosinic-polycytidylic acid is the most effective tlr adjuvant for siv gag protein-induced T cell responses in nonhuman primates. J. Immunol. 2013, 190:4103-4115.
50. Pena L., Moraes M.P., Koster M., Burrage T., Pacheco J.M., Diaz-San Segundo F., Grubman M.J. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructrual protein 2B improves protection of swine. Vaccine 2008, 26:5689-5699.
51. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006, 124:849-863.
52. Sorensen K.J., Madsen K.G., Madsen E.S., Salt J.S., Nqindi J., Mackay D.K. Differentiation of infection from vaccination in foot-and-mouth disease by the detection of antibodies to the non-structural proteins 3D, 3AB and 3ABC in ELISA using antigens expressed in baculovirus. Arch. Virol. 1998, 143:1461-1476.
53. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., Salazar A.M., Uberla K., Nieto K., Kleinschmidt J., Schulte R., Gissmann L., Muller M., Sacher A., Racz P., Steinman R.M., Uguccioni M., Ignatius R. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 2009, 5:1-15.
54. Stephen E.L., Hilmas D.E., Levy H.B., Spertzel R.O. Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J. Infect. Dis. 1979, 139:267-272.
55. Stephen E.L., Sammons M.L., Pannier W.L., Baron S., Spertzel R.O., Levy H.B. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J. Infect. Dis. 1977, 136:122-126.
56. Suhy D.A., Giddings T.H., Kirkegaard K. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. J. Virol. 2000, 74:8953-8965.
57. Tatsis N., Ertl H.C.J. Adenoviruses as vaccine vectors. Mol. Ther. 2004, 10:616-629.
58. Tenbusch M., Ignatius R., Nchinda G., Trumpfheller C., Salazar A.M., Töpfer K., Sauermann U., Wagner R., Hannaman D., Tenner-Racz K., Racz P., Stahl-Hennig C., Uberla K. Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PLoS One 2012, 7:e39038.
59. Wiltrout R.H., Salup R.R., Twilley T.A., Talmadge J.E. Immunomodulation of natural killer activity by polyribonucleotides. J. Biol. Response Modif. 1985, 4:512-517.
60. Wu Q., Brum M.C.S., Caron L., Koster M., Grubman M.J. Adenovirus-mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. J. Int. Cyt. Res. 2003, 23:371-380.
61. Zhou C.-X., Li D., Chen Y.-L., Lu Z.-J., Sun P., Cao Y.-M., Hui-Fang B., Fu Y.-F., Li P.-H., Bai X.-W., Xie B.-X., Liu Z.-X. Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine. BMC Vet. Res. 2014, 10:2. 10.1186/1746-6148-10-2.